特地唑胺 T1747

Product Introduction
Bioactivity


英文名: Tedizolid

描述: Tedizolid (DA-7157)是一种新型恶唑烷酮类抗生素，可与核糖体50S 亚基的23S 核糖体 RNA 结合抑制细菌的蛋白质合成。

体外活性: Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP which is 4-fold more potent than linezolid against PRSP[1].

体内活性: The tedizolid phosphate at a minimum total daily dose of 10 mg/kg achieved a 100% survival rate for mice infected with PSSP type III. Lungs of infected mice treated with tedizolid phosphate show less severe inflammation and edema, as indicated by the mean scores for inflammation and edema[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 2.8 mg/mL (7.56 mM)


关键字: TR-700 | inhibit | DA7157 | Tedizolid | Bacterial | Inhibitor | Antibiotic | DA 7157 | TR700

相关产品: Moclobemide | MAO-B-IN-17 | 4-Hydroxyderricin | Hydroxyamine hydrochloride | AnnH31 | Clorgyline hydrochloride | Salvigenin | Hydralazine hydrochloride | CR4056 | Vafidemstat

相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Mitochondria-Targeted Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Anti-Bacterial Compound Library | Anti-Infection Compound Library

特地唑胺 T1747信息由TargetMol中国为您提供，如您想了解更多关于特地唑胺 T1747报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途